These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 10671671)

  • 61. Estrogen receptor status of breast cancer: a marker of different stages of tumor or different entities of the disease?
    Zhu K; Bernard LJ; Levine RS; Williams SM
    Med Hypotheses; 1997 Jul; 49(1):69-75. PubMed ID: 9247911
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Aggressive angiomyxoma of the vulva: expression of estroprogestinic receptors and follow-up.
    De Salvia D; Fais GF; Lauri F; Brotto M; Petrillo G; Salmaso R
    Clin Exp Obstet Gynecol; 1998; 25(4):141-3. PubMed ID: 9987573
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Urban-rural differences in breast cancer incidence by hormone receptor status across 6 years in Egypt.
    Dey S; Soliman AS; Hablas A; Seifeldin IA; Ismail K; Ramadan M; El-Hamzawy H; Wilson ML; Banerjee M; Boffetta P; Harford J; Merajver SD
    Breast Cancer Res Treat; 2010 Feb; 120(1):149-60. PubMed ID: 19548084
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The pattern of prognostic and risk indicators among women with breast cancer undergoing modified radical mastectomy in Dar es Salaam, Tanzania.
    Mwakigonja AR; Rabiel H; Mbembati NA; Lema LE
    Infect Agent Cancer; 2016; 11():28. PubMed ID: 27366204
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Expression of estrogen and progesterone receptors across human malignancies: new therapeutic opportunities.
    Munoz J; Wheler J; Kurzrock R
    Cancer Metastasis Rev; 2015 Dec; 34(4):547-61. PubMed ID: 25543191
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Characterisation of benign lesions and carcinomas of the female breast in a sub-Saharan African population.
    Mbonde MP; Amir H; Mbembati NA; Holland R; Schwartz-Albiez R; Kitinya JN
    Pathol Res Pract; 1998; 194(9):623-9. PubMed ID: 9793961
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Correlation of estrogen receptor and pathologic characteristics of invasive breast cancer.
    Fisher ER; Redmond CK; Liu H; Rockette H; Fisher B
    Cancer; 1980 Jan; 45(2):349-53. PubMed ID: 7351016
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Steroid receptors in benign breast disease, gross cystic disease and fibroadenoma.
    Nardelli GB; Lamaina V; Siliotti F
    Clin Exp Obstet Gynecol; 1987; 14(1):10-5. PubMed ID: 3815831
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Hyperplastic changes and receptor status in the breast tissue of bodybuilders under anabolic-androgenic steroid stimulation.
    Salazar EL; Torres JA; Avila A; Andrade A
    Arch Androl; 2000; 45(1):1-7. PubMed ID: 10959495
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Significance of the Tritiated Thymidine Labeling Index in breast cancers.
    Araki K; Kimura M; Sakamoto K; Nishimura R; Akagi M
    Jpn J Surg; 1985 Mar; 15(2):144-9. PubMed ID: 4010096
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Relationship between 90-kilodalton heat shock protein, estrogen receptor, and progesterone receptor in human mammary tumors.
    Shyamala G; Schweitzer M; Ullrich SJ
    Breast Cancer Res Treat; 1993; 26(1):95-100. PubMed ID: 8400328
    [TBL] [Abstract][Full Text] [Related]  

  • 72. NOHA: A Promising Biomarker for Determining Estrogen Receptor Status Among Patients With Breast Cancer in Resource-Constrained Settings.
    Serventi F; Musyoka A; Saunders J; Mremi A; Mmbaga BT; Patrick E; Mwakyembe T; Jones M; Lucas FL; Miesfeldt S; Mohan S
    JCO Glob Oncol; 2022 Dec; 8():e2200192. PubMed ID: 36542825
    [TBL] [Abstract][Full Text] [Related]  

  • 73. ASO Author Reflections: Core Needle Biopsy and Hormonal Receptor Retesting in Breast Cancer: Controversy and Management.
    Zhu S; Chen X; Shen K
    Ann Surg Oncol; 2020 Dec; 27(Suppl 3):731-732. PubMed ID: 32661856
    [No Abstract]   [Full Text] [Related]  

  • 74. Diverse pathomechanisms leading to the breakdown of cellular estrogen surveillance and breast cancer development: new therapeutic strategies.
    Suba Z
    Drug Des Devel Ther; 2014; 8():1381-90. PubMed ID: 25246776
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Receptors in breast cancer: an introduction.
    Raynaud JP
    Ann N Y Acad Sci; 1977 Mar; 286():87-9. PubMed ID: 214006
    [No Abstract]   [Full Text] [Related]  

  • 76. Hormonal receptors in cutaneous vascular malformations: 51 cases.
    Ventéjou S; Machet MC; Herbreteau D; le Touze A; Lorette G; Maruani A
    Virchows Arch; 2019 Jun; 474(6):755-761. PubMed ID: 30810814
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Glucose transporters in sex steroid hormone related cancer.
    Nualart F; Los Angeles García M; Medina RA; Owen GI
    Curr Vasc Pharmacol; 2009 Oct; 7(4):534-48. PubMed ID: 19485886
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Human mesenchymal stem cells as mediators of breast carcinoma tumorigenesis and progression.
    Rhodes LV; Burow ME
    ScientificWorldJournal; 2010 Jun; 10():1084-7. PubMed ID: 20563531
    [No Abstract]   [Full Text] [Related]  

  • 79. Breast cancer in Japan and United States: epidemiology, hormone receptors, pathology, and survival.
    Yonemoto RH
    Arch Surg; 1980 Sep; 115(9):1056-62. PubMed ID: 6251779
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Interlaboratory variation in results from immunohistochemical assessment of estrogen receptor status.
    Layfield LJ; Goldstein N; Perkinson KR; Proia AD
    Breast J; 2003; 9(3):257-9. PubMed ID: 12752643
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.